All participants received multiagent chemotherapy. Surgery was performed on 27 (71%) of the 38 patients, 7 of whom (26%) also had HIPEC. 9 (24%) had WAP-RT, and MC was administered to 12 (32%) of the patients. The median duration of follow-up, at 37 months (interquartile range 18-63), revealed a median event-free survival of 15 months and a median…[Read more]